More on KNBWY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $14.60 |
|
|||
| Open | $14.60 | ||||
| 52 Wk High | $18.64 | ||||
| 52 Wk Low | $12.59 | ||||
| Day High | $14.85 | ||||
| Day Low | $14.57 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 49,327 | ||||
- First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
- First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
- Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ® (istradefylline) and Other Parkinson's Disease Add-On Therapies
- Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
- Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
- Kirin Holdings Co Ltd (2503:JP) (KNBWY) PT Lowered to JPY2,200 at Bernstein
- Kyowa Kirin Announce Symposium, Acceptance of Abstract for Presentation at American Academy of Dermatology 2024 Meeting
- BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
- Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema
- New Post Hoc Analysis from MAVORIC Trial Sheds Light on Burden of Cutaneous T-cell Lymphoma on Health-related Quality of Life
Entities mentioned with KNBWY
- FDA | View Related Stories »
- Genzyme/Sanofi-Aventis | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- AdCom | View Related Stories »
- Dividend | View Related Stories »
- Show More...
